Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase I/II Study of the Safety and Efficacy of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Apr 2013
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions
- 02 Apr 2013 New trial record
- 28 Mar 2013 Status changed from not yet recruiting to discontinued, as record deleted from ClincialTrials.gov.